Literature DB >> 12062259

Charcot-Marie-Tooth disease type 2C: a distinct genetic entity. Clinical and molecular characterization of the first European family.

L Santoro1, F Manganelli, L Di Maio, F Barbieri, M Carella, P D'Adamo, G Casari.   

Abstract

Charcot- Marie-Tooth disease type 2 is clinically and genetically heterogeneous. A particular clinical subtype of autosomal dominant Charcot-Marie-Tooth disease type 2, characterized by diaphragm and vocal cord paralysis, is labelled Charcot-Marie-Tooth disease type 2C but no genetic locus has been mapped for this form. We describe the first European family affected by Charcot-Marie-Tooth disease type 2C. Genetic analysis excluded linkage to locus of Charcot-Marie-Tooth disease type 2A, B, D, E and F, and to locus of distal hereditary motor neuronopathy type VII. In this family the disease has high penetrance, variable severity and apparently the most severe limb muscle involvement in the youngest generation. Vocal cord paralysis is unrelated to the degree of muscular weakness and patients with the most severe muscle involvement have absent or minimal respiratory symptoms. Charcot-Marie-Tooth disease type 2C is clinically and genetically different from Charcot-Marie-Tooth disease type 2A, B, D, E and F, and is not allelic with distal hereditary motor neuronopathy type VII.

Entities:  

Mesh:

Year:  2002        PMID: 12062259     DOI: 10.1016/s0960-8966(01)00305-4

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  7 in total

Review 1.  A review of genetic counseling for Charcot Marie Tooth disease (CMT).

Authors:  Carly E Siskind; Seema Panchal; Corrine O Smith; Shawna M E Feely; Joline C Dalton; Alice B Schindler; Karen M Krajewski
Journal:  J Genet Couns       Date:  2013-04-21       Impact factor: 2.537

2.  Dominant mutations in the cation channel gene transient receptor potential vanilloid 4 cause an unusual spectrum of neuropathies.

Authors:  Magdalena Zimoń; Jonathan Baets; Michaela Auer-Grumbach; José Berciano; Antonio Garcia; Eduardo Lopez-Laso; Luciano Merlini; David Hilton-Jones; Meriel McEntagart; Andrew H Crosby; Nina Barisic; Eugen Boltshauser; Christopher E Shaw; Guida Landouré; Christy L Ludlow; Rachelle Gaudet; Henry Houlden; Mary M Reilly; Kenneth H Fischbeck; Charlotte J Sumner; Vincent Timmerman; Albena Jordanova; Peter De Jonghe
Journal:  Brain       Date:  2010-05-11       Impact factor: 13.501

3.  Reduced penetrance in hereditary motor neuropathy caused by TRPV4 Arg269Cys mutation.

Authors:  José Berciano; Jonathan Baets; Elena Gallardo; Magdalena Zimoń; Antonio García; Eduardo López-Laso; Onofre Combarros; Jon Infante; Vincent Timmerman; Albena Jordanova; Peter De Jonghe
Journal:  J Neurol       Date:  2011-02-19       Impact factor: 4.849

Review 4.  Disorders of pulmonary function, sleep, and the upper airway in Charcot-Marie-Tooth disease.

Authors:  Loutfi S Aboussouan; Richard A Lewis; Michael E Shy
Journal:  Lung       Date:  2007-02-09       Impact factor: 2.584

5.  A novel mutation of myelin protein zero associated with an axonal form of Charcot-Marie-Tooth disease.

Authors:  L Santoro; F Manganelli; E Di Maria; D Bordo; D Cassandrini; F Ajmar; P Mandich; E Bellone
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-02       Impact factor: 10.154

6.  Mutations in TRPV4 cause Charcot-Marie-Tooth disease type 2C.

Authors:  Guida Landouré; Anselm A Zdebik; Tara L Martinez; Barrington G Burnett; Horia C Stanescu; Hitoshi Inada; Yijun Shi; Addis A Taye; Lingling Kong; Clare H Munns; Shelly S Choo; Christopher B Phelps; Reema Paudel; Henry Houlden; Christy L Ludlow; Michael J Caterina; Rachelle Gaudet; Robert Kleta; Kenneth H Fischbeck; Charlotte J Sumner
Journal:  Nat Genet       Date:  2009-12-27       Impact factor: 38.330

Review 7.  The genetics of Charcot-Marie-Tooth disease: current trends and future implications for diagnosis and management.

Authors:  J Chad Hoyle; Michael C Isfort; Jennifer Roggenbuck; W David Arnold
Journal:  Appl Clin Genet       Date:  2015-10-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.